Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

NCT01556763 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder
Central Nervous System Diseases

Interventions

DRUG: EVP-6124 (0.3 mg/day)
DRUG: EVP-6124 (1.0 mg/day)
DRUG: Placebo
DRUG: Antipsychotic therapy

Sponsor

FORUM Pharmaceuticals Inc